 | Up a level |
Traversi, Florian; Stooss, Amandine; Dettmer, Matthias S.; Charles, Roch-Philippe (2021). BRAFV600E Overrides NOTCH Signaling in Thyroid Cancer. Thyroid, 31(5), pp. 787-799. Mary Ann Liebert 10.1089/thy.2019.0595
El Mokh, Oussama; Taelmann, Vincent; Radojewski, Piotr; Rölli, Matthias Andreas; Stooss, Amandine; Dumont, Rebecca A; Dettmer, Matthias; Phillips, Wayne; Walter, Martin Alexander; Charles, Roch-Philippe (2019). MEK inhibition induces therapeutic iodine uptake in a murine model of anaplastic thyroid cancer. Journal of nuclear medicine, 60(7), pp. 917-923. Society of Nuclear Medicine 10.2967/jnumed.118.216721
Poirier, Marion; Awale, Mahendra; Rölli, Matthias A.; Giuffredi, Guy T.; Ruddigkeit, Lars; Evensen, Lasse; Stooss, Amandine; Calarco, Serafina; Lorens, James B.; Charles, Roch-Philippe; Reymond, Jean-Louis (2018). Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT-β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2. ChemMedChem, 14(2), pp. 224-236. Wiley-VCH 10.1002/cmdc.201800554
Häfliger, Pascal; Graff, Julien; Rubin, Matthias; Stooss, Amandine; Dettmer, Matthias S.; Altmann, Karl-Heinz; Gertsch, Jürg; Charles, Roch-Philippe (2018). The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model. Journal of experimental & clinical cancer research, 37(1), p. 234. BioMed Central 10.1186/s13046-018-0907-z
Rölli, Matthias Andreas; Ruffieux-Daidiée, Dorothée; Stooss, Amandine; El Mokh, Oussama; Phillips, Wayne A; Dettmer, Matthias; Charles, Roch-Philippe (2017). PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. OncoTarget, 8(61), pp. 103207-103222. Impact Journals LLC 10.18632/oncotarget.21732
El Mokh, Oussama; Ruffieux-Daidié, Dorothée; Rölli, Matthias Andreas; Stooss, Amandine; Phillips, Wayne A; Gertsch, Jürg; Dettmer, Matthias; Charles, Roch-Philippe (2017). Combined MEK and Pi3'-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo. OncoTarget, 8(15), pp. 24604-24620. Impact Journals LLC 10.18632/oncotarget.15599
